The clinical information you need, at your fingertips.

Phase 3 data support first-line targeted combination in this high-risk subgroup. . .

From a stable disease state on biologics, three-quarters were able to maintain low disease activity after stretching injection intervals to two-thirds or half the standard dose. . .

FDG-PET/CT showed coordinated metabolic changes across multiple organs one year after bariatric surgery, extending well beyond weight loss alone. . .

New AHA scientific statement urges clinicians to prioritize physical activity for cardiometabolic health, even when weight loss is modest. . .

Decnupaz (pivekimab sunirine-pvzy) achieved complete remission rates approaching 70% in treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm. . .

Population-based multicancer early detection (MCED) trial linked to modest increases in time to cancer diagnosis. . .

At five years, the personalized mRNA vaccine intismeran added to pembrolizumab continues to cut recurrence and distant metastasis risk in resected high-risk melanoma, with most patients in the combination arm still cancer-free. . .

A novel radiopharmaceutical approach delivered encouraging responses in heavily pretreated patients. . .

The novel cefepime-zidebactam combination outperformed meropenem in a phase 3 trial and adds a new option for multidrug-resistant infections. . .